Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia
Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia
复制标题
DOI：
10.1016/j.urology.2015.01.028
复制
发表时间：
2015-05-01
期刊：
影响因子：
2.1
通讯作者：
Oya, Mototsugu
中科院分区：
文献类型：
--
作者：
Maeda, Takahiro;Kikuchi, Eiji;Oya, Mototsugu
目的评价度他雄胺（DUT）治疗良性前列腺增生（BPH）伴持续性膀胱过度活动症（OAB）患者后，索利那新（SOL）或米拉贝隆（MIR）的临床疗效和不良事件。患者接受5 mg/d SOL（N = 25）或50 mg/d MIR（N = 25），并在4周和12周前瞻性收集国际前列腺症状评分（IPSS）和OABSS。结果DUT治疗后前列腺体积、IPSS和OABSS的平均值分别为39.0mL、17.6和8.1。SOL 5 mg显著降低了4周和12周时的IPSS、OABSS和OABSS Q3（-3.1，-2.7，-1.3; P
OBJECTIVE To evaluate the clinical response and adverse events (AEs) of solifenacin (SOL) or mirabegron (MIR) in benign prostatic hyperplasia patients with persistent overactive bladder (OAB) symptoms after dutasteride (DUT) treatment.METHODS Fifty cases with residual OAB symptom score (OABSS) >= 5 and OABSS Q3 >= 2 after at least 6 months treatment of DUT were included in this study. Patients were administered 5 mg/d of SOL (N = 25) or 50 mg/d of MIR (N = 25), and International Prostate Symptom Score (IPSS) and OABSS were prospectively collected at 4 and 12 weeks. The safety was evaluated by changes in postvoided residual urine volume and the incidence of AEs.RESULTS After DUT administration, the mean prostate volume, IPSS, and OABSS were 39.0 mL, 17.6, and 8.1, respectively. SOL 5 mg significantly reduced the IPSS, OABSS, and OABSS Q3 at 4 and at 12 weeks (-3.1, -2.7, -1.3; P